



**FDC Limited**

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date: 13<sup>th</sup> November 2024

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

**Scrip Code-531599**

**National Stock Exchange of India Ltd.**

Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051

**NSE Symbol- FDC**

**Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and disclosure Requirements) Regulations, 2015.**

Dear Sir/ Madam,

This is further to the intimation given by the Company dated August 23, 2024, the U.S. Food and Drug Administration (FDA) had conducted an inspection at Company's manufacturing facility located at Baddi, Himachal Pradesh in the month of August 2024.

The Company has now received the Establishment Inspection Report (EIR) from US FDA with **"No Observations" (Zero 483's)**. This approval confirms the closure of inspection conducted in August 2024. The Inspection was carried out in relation to the ANDA – Cefuroxime Proxetil tablets and ANDA-Cefixime 400 mg Tablets.

Kindly take the above on record.

Thanking you,

Yours truly,

**For FDC LIMITED**

**Varsharani Katre**

**Company Secretary & Compliance Officer**

**Membership No.: FCS-8948**

---

**CORPORATE OFFICE** : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA  
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462  
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

**REGISTERED OFFICE** : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299  
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176